BIOCHEMISTRY PLAYS A CRITICAL ROLE IN CHRONIC PAIN

With analysis of 11 well-defined urine biomarkers of chronic inflammation, nerve health, neurotransmitter status, and oxidative
stress, Pain Biomarker Assessment provides insight into the possible origins of neuropathic pain, inflammatory pain, and altered
pain perception.
• Pain Biomarker Assessment was informed by a large, retrospective, observational study of 17,834 patients with chronic pain
• 77% of these chronic pain patients exhibited at least one abnormal pain biomarker
• In healthy people with no history of chronic pain or opioid use, up to 5% exhibited one or more of these abnormal biomarkers

FUNCTIONAL BIOMARKER TESTING
Functional Biomarkers in urine to identify sources of pain

Our Functional Biomarker panel enables providers to identify a deficiency, imbalance, or condition that can cause or worsen pain.

Ethos Laboratories, in partnership with Ethos R&D, has developed a series of functional biomarker panels specific to pain. These laboratory tests provide objective measurements of biomarkers known to be associated with pain and may be used as part of a pain specific work up. Analytes included in functional biomarker testing can be classified as markers of the following:

CHRONIC INFLAMMATION

NERVE HEALTH

NEUROTRANSMITTER STATUS

OXIDATIVE STRESS

Functional biomarker testing provides novel, objective information about the biochemical origins of pain. Correcting abnormal biomarker findings with cost-effective, non-opioid therapies provides a valuable adjunct treatment program to maximize the likelihood of successful and prolonged pain management.

77%*

AT LEAST ONE ABNORMAL BIOMARKER

FUNCTIONAL BIOMARKER TESTING PROVIDES NOVEL, OBJECTIVE INFORMATION ABOUT THE BIOCHEMICAL ORIGINS OF PAIN. CORRECTING ABNORMAL BIOMARKER FINDINGS WITH COST-EFFECTIVE, NON-OPIOID THERAPIES PROVIDES A VALUABLE ADJUNCT TREATMENT PROGRAM TO MAXIMIZE THE LIKELIHOOD OF SUCCESSFUL AND PROLONGED PAIN MANAGEMENT.

In a retrospective study of 17,384 patients seeking treatment for chronic pain, 13,765 patients (77%) had at least one abnormal biomarker associated with chronic inflammation, neurotransmitter status, nerve health, and/or oxidative stress. These findings confirm that chronic inflammation, abnormal neurotransmitter turnover, micronutrient deficiencies, and increased oxidative stress play central roles in the development and/or worsening of chronic pain. *Based on analysis of eleven different analytes from 17,300+ functional biomarker samples.

CHRONIC INFLAMMATION INDUCES A TRANSITION FROM TYPICAL SICKNESS BEHAVIOR INTO DEPRESSION AND CHRONIC PAIN

44% exhibited abnormal chronic inflammation biomarkers – 7,649 of 17,384 patients had biomarkers indicative of chronic, systemic inflammation which is known to play a central role in the development of chronic pain.

44%*

CHRONIC INFLAMMATION

MICRONUTRIENT  DEFICIENCIES CAN DIRECTLY DAMAGE NERVES RESULTING IN DEMYELINATION AND AXONAL DEATH

43% exhibited abnormal nerve health biomarkers – 5,737 of 17,384 patients had biomarkers indicative of micronutrient deficiencies which directly impact nerve health. Early stage micronutrient deficiencies can manifest as numbness and tingling in the hands and feet but if left untreated can cause painful neuropathies and demyelination of nerves. Medications including Zantac®, Prilosec®, metformin, isoniazid, and certain diuretics can all precipitate micronutrient deficiencies which worsen pain.

43%*

NERVE HEALTH

OPTIMAL LEVELS OF NEUROTRANSMITTERS ARE REQUIRED FOR THE ACTIVATION OF DESCENDING INHIBITORY PATHWAYS WHICH ACT TO INHIBIT PAIN

7.5% exhibited abnormal neurotransmitter status biomarkers – 1,304 of 17,384 patients had biomarkers indicative of abnormal turnover of the pain modulating neurotransmitters serotonin and norepinephrine.

7.5%*

NEUROTRANSMITTER STATUS

OXIDATIVE STRESS IS KNOWN TO BE IMPLICATED IN THE ETIOLOGY OF PAIN BY INDUCING PERIPHERAL & CENTRAL HYPERALGESIA 

44% exhibited abnormal oxidative stress biomarkers – 5,389 of 17,384 patients had biomarkers indicative of oxidative stress and/or damage. Individuals with a decreased ability to combat oxidative stress are more likely to develop chronic pain as a result of oxidative damage to nerve cells.

44%*

OXIDATIVE STRESS